A Phase 1 interventional study of GLPG2737 single dose in Cystic Fibrosis, sponsored by Galapagos NV. Completed at 1 site in Belgium. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-19.
Sponsored by Galapagos NV · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Cystic Fibrosis with a site in Belgium — 6 open to participants now, 9 under way, 2 of them phase 3. Cystic Fibrosis · Belgium.
Among the 118 studies in Cystic Fibrosis with a site in Belgium, this one is the 96th largest by enrollment of the 101 interventional ones that give a count, is one of 11 that started in 2017, is one of 5 in phase 1, and was the 70th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →6 of the 118 studies in Cystic Fibrosis with a site in Belgium are open now. Recruiting first, the newest first:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Sites in Belgium
Healthy volunteers
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Erasme University Hospital · Sites in Belgium
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
Paragonix Technologies · Sites in Belgium, United States
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 31 · Phase 3 41 · Phase 4 4
First in 2001; this study’s year is marked. 11 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 78 across the 101 interventional studies, 100 across the 17 observational. Of the 98 that completed or were terminated, 58 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
71 of 118 have an industry lead sponsor. The 10 most frequent:
This study is registered under Galapagos NV, one of the names counted as Lakefront Biotherapeutics NV. Under that name alone:
Galapagos NV is the lead sponsor of 103 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.
Lakefront Biotherapeutics NV has 8 studies filed under Cystic Fibrosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Cystic Fibrosis with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
Add it to your calendar (.ics) → With an account.
Among the 118 studies in Cystic Fibrosis with a site in Belgium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a single dose, open label study in adult male subjects with cystic fibrosis to investigate the pharmacokinetics, safety and tolerability of GLPG2737.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of GLPG2737 oral suspension.
Drug: GLPG2737 single dose
GLPG2737 oral suspension, single dose
Maximum observed plasma concentration (Cmax) of GLPG2737and its metabolite.
To characterize the PK of GLPG2737 and its metabolite after a single oral dose in CF subjects.
Time frame: Between day 1 pre-dose and 48 hours post-dose.
Time of occurrence of Cmax for GLPG2737(tmax)
To determine PK parameters of GLPG2737 and its metabolite after given a single oral dose in CF subjects.
Time frame: Between day 1 pre-dose and 48 hours post-dose.
Plasma concentration observed at 24 hours post-dos (C24h)
To assess PK parameters of GLPG2737 and its metabolite after given a single oral dose in CF subjects.
Time frame: Between day 1 pre-dose and 48 hours post-dose.
Area under the plasma concentration-time curve for GLPG2737 (AUC0-24h)
To determine the PK of GLPG2737 and its metabolite after a single oral dose in CF subjects.
Time frame: Between day 1 pre-dose and 48 hours post-dose.
Area under the plasma concentration-time curve from time zero until 48 hours post-dose (AUC0-48h)
To determine the PK of GLPG2737 and its metabolite after a single oral dose in CF subjects.
Time frame: Between day 1 pre-dose and 48 hours post-dose.
Terminal plasma elimination rate constant (ke)
To determine the PK of GLPG2737 and its metabolite after a single oral dose in CF subjects.
Time frame: Between day 1 pre-dose and 48 hours post-dose.
Apparent terminal elimination half-life ( t1/2)
To determine the PK of GLPG2737 and its metabolite after a single oral dose in CF subjects.
Time frame: Between day 1 pre-dose and 48 hours post-dose.
Number of subjects with adverse events.
To determine the safety and tolerability of GLPG2737 after a single oral dose in CF subjects.
Time frame: Between screening and 15 days post-dose
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jun 2017 to primary completion in Aug 2017, 1 month.
Of 39 industry-sponsored phase 1 interventional studies under Cystic Fibrosis, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 1 month is below that.
Counting every sponsor, half of 62 studies reached it within 10 months; a quarter within 5 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG-2737